Mechanism of Action
Reimbursement / eHealth
Beovu® (brolucizumab) is reimbursed in Grand-Duché de Luxembourg, not in Belgium.
Twitter Linkedin Facebook Pinterest Google plusSafety profile
▼Beovu ® (brolucizumab) is indicated in adults for the treatment of neovascular (wet) AMD and visual impairment due to DME 1 Safety profile with Beovu in clinical trials Beovu exhibited an overall well-tolerated safety...
Twitter Linkedin Facebook Pinterest Google plusEfficacy
Wet AMD Visual acuity and outcomes with Beovu in clinical trialsAt Week 48, brolucizumab demonstrated non-inferiority to aflibercept in mean BCVA change from baseline in HAWK (p<0.001). • Visual acuity gains achieved at Week 48...
Twitter Linkedin Facebook Pinterest Google plusIndications
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report...
Twitter Linkedin Facebook Pinterest Google plusMPN Partner
PIONEER-HF
The recently presented PIONEER-HF studies the efficacy and safety of initiating ENTRESTO compared to enalapril prior to discharge after hospitalization for an acute decompensated heart failure episode. 1 The results of PIONEER-HF...
Twitter Linkedin Facebook Pinterest Google plusEntresto® (Sacubitril/Valsartan)
ENTRESTO ® is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction. ENTRESTO ® is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure...Twitter Linkedin Facebook Pinterest Google plusWerkzaamheid
1. Richtlijnen voor behandelingIn de afgelopen 10 jaar heeft het behandelingslandschap van SpA een substantiële verandering ondergaan, met een uitbreiding van nieuwe therapieën en nieuwe werkingsmechanismen. Er zijn richtlijnen en...
Twitter Linkedin Facebook Pinterest Google plus